Arrhythmia Research Technology (HRT) Reports Q1 EPS of $0.09

Arrhythmia Research Technology (AMEX: HRT) reported Q1 EPS of $0.09, versus $0.00 reported last year. Revenue for the quarter came in at $6.03 million, versus $5.64 million reported last year.

Salvatore Emma, Jr., the Company's President and CEO, commented, "We had a solid first quarter that reflects the many changes we have been making in the Company, including realigned product focus, cost discipline, LEAN production processes and identifying new opportunities for our specialized engineering design and manufacturing capabilities. A favorable mix of products, such as orthopedic implant components and software licenses, helped to improve margin in the quarter. Of note, we have increased our research and development efforts as new products, customers and capabilities will drive the future for the Company."

For earnings history and earnings-related data on Arrhythmia Research Technology (HRT) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Star Equity to acquire Harte Hanks for $5 per share in cash and stock
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c